ArticleFrontiers in oncology2026
Efficacy, toxicity, and prognostic factors of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in elderly patients with diffuse large B-cell lymphoma: a single-center retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Optimizing treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL) remains clinically challenging because curative intent must be balanced against treatment-related toxicity and reduced treatment tolerance. This study aimed to evaluate the efficacy and toxicity of first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-based treatment in elderly patients with DLBCL and to identify prognostic factors associated with overall survival. Methods: We conducted a single-center retrospective cohort study of 162 patients aged 60 years or older with newly diagnosed DLBCL who received first-line R-CHOP-based treatment. The main outcomes were overall survival, treatment delivery, and treatment-related toxicity. Relative dose intensity (RDI) was used to assess treatment delivery, and survival was analyzed using Kaplan-Meier methods and Cox proportional hazards regression. A study-specific geriatric-treatment delivery risk model was further evaluated and compared with the International Prognostic Index (IPI) using discrimination analysis. Results: Patients older than 80 years had a significantly lower median RDI than those aged 60 to 80 years (78.2% vs. 93.6%, P = 0.009) and a markedly higher treatment-related mortality rate (33.3% vs. 1.9%, P = 0.015). In multivariable analysis, RDI below 85% (hazard ratio [HR], 2.45; P< 0.001) and albumin below 35 g/L (HR, 2.03; P< 0.001) were independently associated with worse overall survival. The geriatric-treatment delivery risk model showed better discriminative performance than the conventional IPI, with a concordance index of 0.748. Conclusions: In elderly patients with DLBCL, survival outcomes were closely associated with treatment tolerance and baseline nutritional status. These findings suggest that supportive strategies aimed at preserving treatment delivery, rather than empiric age-based dose reduction alone, may improve clinical outcomes in appropriately selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.